BioCentury | May 11, 2018
Finance

Seroquel stepping stone

The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma’s internal CNS pipeline....
BC Week In Review | May 11, 2018
Company News

Luye acquires AstraZeneca antipsychoitic for $538M

AstraZeneca plc (NYSE:AZN; LSE:AZN) granted Luye Pharma Group Ltd. (HKSE:2186) territorial rights to antipsychotic drug Seroquel quetiapine fumarate and its extended release formulation, Seroquel XL. Luye received rights in 51 countries and regions including China,...
BC Extra | May 7, 2018
Company News

Luye paying AZ $538M for antipsychotic

AstraZeneca plc (NYSE:AZN; LSE:AZN) granted Luye Pharma Group Ltd. (HKSE:2186) territorial rights to antipsychotic drug Seroquel quetiapine fumarate and its extended release formulation, Seroquel XL. Luye received rights in 51 countries and regions including China,...
BC Extra | Oct 29, 2015
Company News

UCB gains after boosting guidance

UCB Group (Euronext:UCB) gained EUR 4.29 to EUR 75.81 on Wednesday after reporting 3Q15 earnings and raising its guidance for 2015. The company raised its revenue guidance to EUR 3.75 billion ($4.14 billion) from a...
BioCentury | Sep 7, 2015
Strategy

Back to School: Changing the subject

No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
BC Week In Review | Jun 22, 2015
Clinical News

Neupro rotigotine: Phase III data

A double-blind, Chinese Phase III trial in 247 adults with early stage idiopathic PD showed that once-daily 2-8 mg transdermal Neupro met the primary endpoint of reducing the sum of the total score of the...
BC Extra | Jun 17, 2015
Clinical News

UCB's Neupro meets in Chinese Phase III PD trial

UCB Group (Euronext:UCB) reported detailed data from a Phase III trial of Neupro rotigotine in Chinese patients with early stage Parkinson's disease (PD). The company announced top-line results in February. UCB plans to submit a...
BioCentury | Oct 27, 2014
Finance

Waiting for better times

Poised to complete the fourth-largest European biotech IPO since 2008, the road show for Molecular Partners AG had the poor luck of coinciding with the largest one-week drop in the broader capital markets since the...
BioCentury | Aug 4, 2014
Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
BioCentury | Apr 28, 2014
Finance

Venture hots up

Private biotechs have raised $3.1 billion since the start of the year, double the $1.5 billion raised in the same period last year. At least one investor contacted by BioCentury expects the pace to continue...
Items per page:
1 - 10 of 127